Axogen (AXGN) Insider Wendell Amy Mcbride Buys 4,392 Shares

Insider Buying and Selling at Axogen, Inc.

On June 24, 2026, Wendell Amy Mcbride bought 4,392 shares of Axogen, Inc. (AXGN) at $44.93 each, which totals about $197,000 based on the current share price. This buy reflects confidence in the company's future prospects, especially as multiple insiders made similar purchases on the same day.

Other Insiders Active on the Same Day

On the same day, several other insiders also increased their stakes in Axogen. Alan Levine, John Johnson, Burke William Mr., Joseph Tyndall, and Weiler Kathy Johnson each bought 4,392 shares, while Paul Thomas acquired 5,579 shares. This coordinated buying activity suggests a strong belief in the company's direction.

Stock Performance and Current Position

Axogen's stock is currently trading near its 52-week high of $52.91, reflecting positive sentiment in the market. The stock has shown significant growth, particularly in the last year, as it climbed from a low of $15.27. The recent insider purchases come at a time when the stock is gaining traction, suggesting insiders believe it still has room to grow.

Analysts Set New Price Targets

Analysts have a positive outlook on Axogen, with a consensus rating of 'strong buy'. The average price target is currently set at $53.90, with several firms initiating coverage recently. For instance, B of A Securities initiated a 'Buy' rating with a target of $52.00 on October 12, 2026, while Barclays set a target of $55.00 on October 7, 2026. This bullish sentiment from analysts aligns with the recent insider buying activity.

What Axogen, Inc. Does

Axogen, Inc. is involved in developing and commercializing technologies for peripheral nerve regeneration and repair. The company offers various products aimed at surgical repair of nerve damage, serving hospitals and surgery centers. The recent insider activity highlights confidence in its growth potential within the medical devices sector.

What’s Next for Axogen

Investors will be watching for Axogen's next earnings report, scheduled for October 28, 2026. As a reminder, the insider trades reflect positions as of the transaction date and may not represent current holdings. With the positive analyst outlook and recent insider confidence, the upcoming earnings could be pivotal for the company.